AXIOS February 21, 2024
A new class of cancer treatments that harness the body’s immune system to fight tumors is being hailed as the biggest thing in oncology since CAR-T revealed the promise of cell therapy more than a decade ago.
- But with price tags of hundreds of thousands of dollars, the drugs raise familiar concerns about affordability and access.
Why it matters: While CAR-T has been successful in some blood cancers, it’s not yet been approved for solid tumors, which make up about 90% of cancer types. The new therapy class — tumor-infiltrating lymphocytes, or TIL — uses immune cells from a patient’s tumor to mount a long-lasting defense.
Driving the news: The Food and Drug Administration last week gave the...
Today's Sponsors
Today's Sponsor